Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNASDAQ:BGMNASDAQ:CDTXNASDAQ:DYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$57.79+0.9%$66.49$52.50▼$77.00$1.25B0.56302,086 shs244,161 shsBGMQilian International Holding Group$14.66+14.2%$11.18$5.26▼$14.78$1.43B1.3326,303 shs19,699 shsCDTXCidara Therapeutics$24.28-5.5%$20.72$10.14▼$28.42$304.64M0.8678,223 shs163,459 shsDYNDyne Therapeutics$11.69-1.8%$10.32$6.36▼$47.45$1.33B1.191.64 million shs1.47 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.91%-3.67%-15.47%-0.26%-6.28%BGMQilian International Holding Group+14.17%+16.91%+34.00%+44.79%+1,465,999,900.00%CDTXCidara Therapeutics-5.53%-4.78%+10.87%+13.09%+96.76%DYNDyne Therapeutics-1.76%-1.18%+8.39%-16.56%-62.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals4.8152 of 5 stars4.53.00.03.33.93.31.3BGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/ACDTXCidara Therapeutics4.3856 of 5 stars4.64.00.04.62.10.80.0DYNDyne Therapeutics3.4769 of 5 stars4.52.00.00.03.14.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$80.1338.65% UpsideBGMQilian International Holding Group 0.00N/AN/AN/ACDTXCidara Therapeutics 3.22Buy$41.8672.39% UpsideDYNDyne Therapeutics 3.07Buy$47.25304.19% UpsideCurrent Analyst Ratings BreakdownLatest CDTX, DYN, ANIP, and BGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CDTXCidara TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$31.00 ➝ $35.005/23/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.005/16/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $50.005/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.005/9/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$33.00 ➝ $35.005/9/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$46.00 ➝ $47.005/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.004/29/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$46.00 ➝ $46.004/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.004/11/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$674.07M1.86$6.40 per share9.03$21.13 per share2.73BGMQilian International Holding Group$25.10M56.79N/AN/A$6.10 per share2.40CDTXCidara Therapeutics$302K1,008.75N/AN/A($1.82) per share-13.34DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$18.78M-$1.27N/A13.73N/A-1.28%15.87%6.88%8/5/2025 (Estimated)BGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/ACDTXCidara Therapeutics-$22.93M-$29.47N/AN/AN/A-289.05%-69.64%-33.73%8/11/2025 (Estimated)DYNDyne Therapeutics-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%8/11/2025 (Estimated)Latest CDTX, DYN, ANIP, and BGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45-$1.66+$3.79-$1.66N/AN/A5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A3/6/2025Q4 2024CDTXCidara Therapeutics-$5.28-$5.38-$0.10-$5.37N/AN/A3/4/2025Q4 2024DYNDyne Therapeutics-$0.92-$0.88+$0.04-$0.88N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/ABGMQilian International Holding GroupN/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.522.741.97BGMQilian International Holding GroupN/A3.392.82CDTXCidara TherapeuticsN/A3.543.54DYNDyne TherapeuticsN/A17.0217.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%BGMQilian International Holding GroupN/ACDTXCidara Therapeutics35.82%DYNDyne Therapeutics96.68%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%BGMQilian International Holding Group58.66%CDTXCidara Therapeutics3.89%DYNDyne Therapeutics20.77%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million18.36 millionOptionableBGMQilian International Holding Group29897.22 million2.48 millionN/ACDTXCidara Therapeutics9012.55 million6.51 millionNo DataDYNDyne Therapeutics100113.67 million80.63 millionOptionableCDTX, DYN, ANIP, and BGM HeadlinesRecent News About These CompaniesDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Purchased by D. E. Shaw & Co. Inc.May 21 at 4:03 AM | marketbeat.com66,998 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by BNP Paribas Financial MarketsMay 21 at 3:27 AM | marketbeat.comPoint72 Asset Management L.P. Purchases 822,201 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)May 20, 2025 | marketbeat.comMan Group plc Has $17.59 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)May 19, 2025 | marketbeat.comSphera Funds Management LTD. Grows Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)May 18, 2025 | marketbeat.comRTW Investments LP Sells 1,600,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)May 18, 2025 | marketbeat.comDyne Reports on Response Predictive Biomarkers for Neurodegenerative Disorder Genetic MedicineMay 17, 2025 | precisionmedicineonline.comDimensional Fund Advisors LP Sells 66,569 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)May 17, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Position Boosted by Comerica BankMay 16, 2025 | marketbeat.comNorthern Trust Corp Increases Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)May 16, 2025 | marketbeat.comWhy Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 7.11%May 15, 2025 | aaii.comOrbimed Advisors LLC Purchases 518,680 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)May 15, 2025 | marketbeat.comOctagon Capital Advisors LP Has $15.74 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)May 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Invests $3.53 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN)May 14, 2025 | marketbeat.comJanus Henderson Group PLC Has $173.81 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)May 14, 2025 | marketbeat.comJefferies Financial Group Inc. Buys Shares of 1,800,000 Dyne Therapeutics, Inc. (NASDAQ:DYN)May 13, 2025 | marketbeat.comCubist Systematic Strategies LLC Buys Shares of 119,065 Dyne Therapeutics, Inc. (NASDAQ:DYN)May 13, 2025 | marketbeat.comBalyasny Asset Management L.P. Cuts Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)May 13, 2025 | marketbeat.comFrontier Capital Management Co. LLC Buys Shares of 298,052 Dyne Therapeutics, Inc. (NASDAQ:DYN)May 12, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Price Target Cut to $38.00 by Analysts at HC WainwrightMay 11, 2025 | marketbeat.comChardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)May 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongAfter Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsStrategists Say Hold: Stocks May Beat the 'Sell in May' TrendBy Jeffrey Neal Johnson | May 9, 2025View Strategists Say Hold: Stocks May Beat the 'Sell in May' TrendWingstop Stock Jumps on Q1 Beat, Expansion OutlookBy Jeffrey Neal Johnson | May 4, 2025View Wingstop Stock Jumps on Q1 Beat, Expansion OutlookCDTX, DYN, ANIP, and BGM Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$57.79 +0.52 (+0.91%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$57.77 -0.02 (-0.03%) As of 05/23/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Qilian International Holding Group NASDAQ:BGM$14.66 +1.82 (+14.17%) Closing price 05/23/2025 03:48 PM EasternExtended Trading$14.10 -0.57 (-3.85%) As of 05/23/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Cidara Therapeutics NASDAQ:CDTX$24.28 -1.42 (-5.53%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$24.35 +0.07 (+0.29%) As of 05/23/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Dyne Therapeutics NASDAQ:DYN$11.69 -0.21 (-1.76%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$11.68 0.00 (-0.04%) As of 05/23/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
